[Neuroimaging in Dementia Diagnosis:Up to Date]

With the clinical application of monoclonal antibody therapy for Alzheimer's disease (AD), diagnostic techniques are shifting toward molecular-targeted imaging. The development of tracers for positron emission tomography (PET) targeting abnormal proteins associated with the disease, such as amyloid-beta and tau, has enabled the detection of neuropathological changes in AD in vivo. This study will contribute to the clinical diagnosis, staging, and monitoring of potential therapeutic approaches for AD. In general outpatient care, imaging modalities that employ widely available techniques such as magnetic resonance imaging or single-photon emission computed tomography remain necessary. This article provides a synopsis of the American College of Radiology recommendations concerning the clinical utility of neuroimaging techniques and reviews the temporal progression of in vivo pathologies derived from amyloid and tau PETs. We investigated the methods for distinguishing between the AD continuum and SNAP in patients with mild cognitive impairment using the ADNI database. Accurate assessment of the "cortical signature" is essential for the diagnosis of AD. Voxel-based morphometry is a useful tool because cortical atrophy is associated with the extension of tau PET lesions. Confirmation of cortical atrophy in conjunction with hippocampal atrophy offers diagnostic insights that facilitate the identification of AD.